Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.

[1]  C. Mueller,et al.  Immune responses in cystic fibrosis: are they intrinsically defective? , 2012, American journal of respiratory cell and molecular biology.

[2]  I. Graham,et al.  Oxylipin Signaling: A Distinct Role for the Jasmonic Acid Precursor cis-(+)-12-Oxo-Phytodienoic Acid (cis-OPDA) , 2012, Front. Plant Sci..

[3]  A. Dávalos,et al.  Molecular Targets of Omega 3 and Conjugated Linoleic Fatty Acids – “Micromanaging” Cellular Response , 2012, Front. Physio..

[4]  A. Landar,et al.  Cell signalling by reactive lipid species: new concepts and molecular mechanisms , 2012, The Biochemical journal.

[5]  M. Laposata,et al.  DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity , 2012, Journal of Lipid Research.

[6]  Laura R. Emery,et al.  Protein Phylogenetic Analysis of Ca2+/cation Antiporters and Insights into their Evolution in Plants , 2012, Front. Plant Sci..

[7]  J. M. Dow,et al.  Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa , 2011, The ISME Journal.

[8]  K. Massey,et al.  Lipidomics of polyunsaturated-fatty-acid-derived oxygenated metabolites. , 2011, Biochemical Society transactions.

[9]  R. Chapkin,et al.  n-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization. , 2011, Chemistry and physics of lipids.

[10]  M. Laposata,et al.  Increased Δ5- and Δ6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis. , 2011, Biochimica et biophysica acta.

[11]  S. Dahlén,et al.  Lipid mediator profiling in pulmonary disease. , 2011, Current pharmaceutical biotechnology.

[12]  M. Drumm,et al.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. , 2011, American journal of respiratory cell and molecular biology.

[13]  E. Kerem,et al.  Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. , 2011, American journal of respiratory and critical care medicine.

[14]  O. Umunakwe,et al.  Increased Elongase 6 and Δ9-Desaturase Activity are Associated with n-7 and n-9 Fatty Acid Changes in Cystic Fibrosis , 2011, Lipids.

[15]  J. Haeggström,et al.  Leukotriene B4/antimicrobial peptide LL‐37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1 , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Daniele Piomelli,et al.  Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients , 2011, Journal of Lipid Research.

[17]  Douglas C Johnson,et al.  Airway mucus function and dysfunction. , 2011, The New England journal of medicine.

[18]  Xinmin Yin,et al.  Natural Forms of Vitamin E and 13′-Carboxychromanol, a Long-Chain Vitamin E Metabolite, Inhibit Leukotriene Generation from Stimulated Neutrophils by Blocking Calcium Influx and Suppressing 5-Lipoxygenase Activity, Respectively , 2011, The Journal of Immunology.

[19]  B. Morrissey,et al.  Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase , 2011, Free radical research.

[20]  S. Quattrucci,et al.  Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis , 2010, Lipids in Health and Disease.

[21]  C. Serhan.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? , 2010, The American journal of pathology.

[22]  S. Hazen,et al.  Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[S] , 2010, Journal of Lipid Research.

[23]  N. Žarković,et al.  Advances in methods for the determination of biologically relevant lipid peroxidation products , 2010, Free radical research.

[24]  T. Wienker,et al.  Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia , 2010, Journal of Medical Genetics.

[25]  Michael Eiden,et al.  Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. , 2010, Analytical chemistry.

[26]  M. Konstan,et al.  Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[27]  Z. Bebők,et al.  Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator , 2010, Expert review of proteomics.

[28]  Suzanne Cheng,et al.  Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis , 2010, European Journal of Human Genetics.

[29]  N. Vij,et al.  The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. , 2010, Discovery medicine.

[30]  B. Rubin,et al.  TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. , 2010, American journal of respiratory cell and molecular biology.

[31]  R. Krauss,et al.  Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study , 2010, Metabolomics.

[32]  B. Levy,et al.  Lovastatin Decreases Acute Mucosal Inflammation Via 15-epi-Lipoxin A4 , 2010, Mucosal Immunology.

[33]  F. Soriguer,et al.  Fatty Acid Supplementation Improves Respiratory, Inflammatory and Nutritional Parameters in Adults with Cystic Fibrosis , 2010 .

[34]  G. Rojo-Martínez,et al.  La suplementación con ácidos grasos mejora parámetros respiratorios, inflamatorios y nutricionales en adultos con fibrosis quística , 2010 .

[35]  G. O’Toole,et al.  Crystal Structure of the Cystic Fibrosis Transmembrane Conductance Regulator Inhibitory Factor Cif Reveals Novel Active-Site Features of an Epoxide Hydrolase Virulence Factor , 2010, Journal of bacteriology.

[36]  M. Hamberg,et al.  Biochemical Characterization of the Oxygenation of Unsaturated Fatty Acids by the Dioxygenase and Hydroperoxide Isomerase of Pseudomonas aeruginosa 42A2 , 2010, The Journal of Biological Chemistry.

[37]  J. Takeda,et al.  The Anti-Inflammatory and Proresolving Mediator Resolvin E1 Protects Mice from Bacterial Pneumonia and Acute Lung Injury , 2009, The Journal of Immunology.

[38]  D. Gilroy,et al.  A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties , 2009, The Journal of Immunology.

[39]  Andrew M. Jones,et al.  Emerging Treatments in Cystic Fibrosis , 2009, Drugs.

[40]  Jun Yang,et al.  Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. , 2009, Analytical chemistry.

[41]  M. Boaz,et al.  Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. , 2009, The American journal of clinical nutrition.

[42]  I. Adcock,et al.  Glucocorticoid resistance in inflammatory diseases , 2009, The Lancet.

[43]  E. Gulbins,et al.  Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease , 2009, Cellular microbiology.

[44]  T. M. O’Connell,et al.  Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[45]  G. Cutting,et al.  Update on gene modifiers in cystic fibrosis , 2008, Current opinion in pulmonary medicine.

[46]  L. Tsui,et al.  Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR , 2008, European Respiratory Journal.

[47]  K. Gronert.  Lipid autacoids in inflammation and injury responses: a matter of privilege. , 2008, Molecular interventions.

[48]  A. Christophe,et al.  Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[49]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[50]  S. Freedman,et al.  Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[51]  J. Carlin,et al.  Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. , 2007, Clinical chemistry.

[52]  M. Whiteley,et al.  Nutritional Cues Control Pseudomonas aeruginosa Multicellular Behavior in Cystic Fibrosis Sputum , 2007, Journal of bacteriology.

[53]  M. Konstan,et al.  Sputum biomarkers of inflammation in cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.

[54]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[55]  J. Christman,et al.  Airway Epithelium Controls Lung Inflammation and Injury through the NF-κB Pathway1 , 2007, The Journal of Immunology.

[56]  G. O’Toole,et al.  The Pseudomonas aeruginosa Secreted Protein PA2934 Decreases Apical Membrane Expression of the Cystic Fibrosis Transmembrane Conductance Regulator , 2007, Infection and Immunity.

[57]  B. Levy,et al.  Lipid mediators as agonists for the resolution of acute lung inflammation and injury. , 2007, American journal of respiratory cell and molecular biology.

[58]  N. Misso,et al.  Oxidative stress and lipid‐derived inflammatory mediators during acute exacerbations of cystic fibrosis , 2007, Respirology.

[59]  E. Rietschel,et al.  Anti-inflammatory cytokines in cystic fibrosis lung disease , 2006, European Respiratory Journal.

[60]  T. Machen.  Innate immune response in CF airway epithelia: hyperinflammatory? , 2006, American journal of physiology. Cell physiology.

[61]  J. Christman,et al.  Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[62]  J. Whitsett,et al.  Functional Genomic Responses to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and CFTRΔ508 in the Lung* , 2006, Journal of Biological Chemistry.

[63]  A. M. Saliba,et al.  Eicosanoid‐mediated proinflammatory activity of Pseudomonas aeruginosa ExoU , 2005, Cellular microbiology.

[64]  P. Bye,et al.  Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. , 2005, American journal of respiratory and critical care medicine.

[65]  H. Heijerman.  Infection and inflammation in cystic fibrosis: a short review. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[66]  P. Burney,et al.  The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. , 2005, American journal of respiratory and critical care medicine.

[67]  J. Feix,et al.  Characterization of Phospholipase Activity of the Pseudomonas aeruginosa Type III Cytotoxin, ExoU , 2005, Journal of bacteriology.

[68]  Erik J. Saude,et al.  NMR analysis of neutrophil activation in sputum samples from patients with cystic fibrosis , 2004, Magnetic resonance in medicine.

[69]  A. Tanswell,et al.  Lung inflammation as a therapeutic target in cystic fibrosis. , 2004, American journal of respiratory cell and molecular biology.

[70]  D. Frank,et al.  ExoU is a potent intracellular phospholipase , 2004, Molecular microbiology.

[71]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[72]  D. Takai,et al.  New therapeutic key for cystic fibrosis: a role for lipoxins , 2004, Nature Immunology.

[73]  J. Mekalanos,et al.  The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. Regan,et al.  Association of cystic fibrosis with abnormalities in fatty acid metabolism. , 2004, The New England journal of medicine.

[75]  M. Lei,et al.  The mechanism of action of the Pseudomonas aeruginosa‐encoded type III cytotoxin, ExoU , 2003, The EMBO journal.

[76]  M. Konstan,et al.  The role of inflammation in the pathophysiology of CF lung disease , 2002, Clinical reviews in allergy & immunology.

[77]  J. Christman,et al.  Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[78]  B. Hammock,et al.  Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase , 1997, Nature Medicine.

[79]  P. J. Byard,et al.  Effect of high-dose ibuprofen in patients with cystic fibrosis. , 1995, The New England journal of medicine.

[80]  M. Konstan,et al.  Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. , 1993, The American review of respiratory disease.

[81]  T. Sorrell,et al.  Bacterial metabolism of human polymorphonuclear leukocyte-derived arachidonic acid , 1992, Infection and immunity.

[82]  C. P. Green,et al.  Leukotrienes in the sputum and urine of cystic fibrosis children. , 1990, British journal of clinical pharmacology.

[83]  J. Zakrzewski,et al.  Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. , 1987, The American review of respiratory disease.

[84]  B. Strandvik,et al.  Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[85]  H. Kase,et al.  Studies on lipoxygenase inhibitors. II. KF8940 (2-n-heptyl-4-hydroxyquinoline-N-oxide), a potent and selective inhibitor of 5-lipoxygenase, produced by Pseudomonas methanica. , 1986, The Journal of antibiotics.

[86]  M. Lebowitz,et al.  Changes in the normal maximal expiratory flow-volume curve with growth and aging. , 1983, The American review of respiratory disease.

[87]  W. Vaughan,et al.  Serum lipoprotein concentrations in cystic fibrosis. , 1978, Science.

[88]  C. W. Moss,et al.  Cellular fatty acid composition of selected Pseudomonas species. , 1972, Applied microbiology.

[89]  J. Zieleński,et al.  Prostaglandin-endoperoxide synthase genesCOX1 andCOX2 — novel modifiers of disease severity in cystic fibrosis patients , 2011, Journal of Applied Genetics.

[90]  D. Gilroy,et al.  Old and new generation lipid mediators in acute inflammation and resolution. , 2011, Progress in lipid research.

[91]  E. Nash,et al.  Prevalence of dyslipidemia in adults with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[92]  F. Soriguer,et al.  Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. , 2010, Archivos de bronconeumologia.

[93]  A. Christophe,et al.  Oral DHA supplementation in F508 homozygous cystic fibrosis patients. , 2008 .

[94]  H. Forman,et al.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. , 2007, Free radical biology & medicine.

[95]  Yan Lu,et al.  Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. , 2007, Methods in enzymology.

[96]  B. Strandvik.  Fatty acid metabolism in cystic fibrosis. , 2004, The New England journal of medicine.

[97]  J. Zakrzewski,et al.  Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay. , 1987, British journal of clinical pharmacology.

[98]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.